ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People's Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal tri… Read more
Market Cap & Net Worth: ABBISKO CAYMAN DL-00001 (8ZD)
ABBISKO CAYMAN DL-00001 (F:8ZD) has a market capitalization of $927.79 Million (€903.86 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #9468 globally and #1019 in its home market, demonstrating a 11.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABBISKO CAYMAN DL-00001's stock price €1.37 by its total outstanding shares 659753350 (659.75 Million).
ABBISKO CAYMAN DL-00001 Market Cap History: 2021 to 2026
ABBISKO CAYMAN DL-00001's market capitalization history from 2021 to 2026. Data shows growth from $653.52 Million to $927.79 Million (3.38% CAGR).
ABBISKO CAYMAN DL-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABBISKO CAYMAN DL-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8ZD by Market Capitalization
Companies near ABBISKO CAYMAN DL-00001 in the global market cap rankings as of March 19, 2026.
Key companies related to ABBISKO CAYMAN DL-00001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ABBISKO CAYMAN DL-00001 Historical Marketcap From 2021 to 2026
Between 2021 and today, ABBISKO CAYMAN DL-00001's market cap moved from $653.52 Million to $ 927.79 Million, with a yearly change of 3.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €927.79 Million | 0.00% |
| 2025 | €927.79 Million | +160.95% |
| 2024 | €355.54 Million | +24.41% |
| 2023 | €285.79 Million | +6.57% |
| 2022 | €268.18 Million | -58.96% |
| 2021 | €653.52 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of ABBISKO CAYMAN DL-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $927.79 Million USD |
| MoneyControl | $927.79 Million USD |
| MarketWatch | $927.79 Million USD |
| marketcap.company | $927.79 Million USD |
| Reuters | $927.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.